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AbstractFCatheter-related sepsis is a serious and common complication inpatients receivinghomeparenteral nutrition
(HPN). Prevention measures, prevalence of infections, types of agents and implanted central venous catheters (CVC),
effectiveness of antibiotic therapy have been evaluated in 221patients consecutively followed in our unit fromJanuary
1995 to December 2000. The clinical diagnosis of catheter-related infection was made using well-defined criteria. Pa-
tients were divided into two groups: A and B, receiving instructions with different modalities: standard (A) and detailed
(B), respectively. Sixty CVC-related sepsis occurred in 32 (14%) patients. A multivariate analysis showed that the dura-
tion of HPN (Po0.001; OR=0.9), type of catheter (P=0.009; OR=0.12) and type of disease (P=0.033; OR=4.92)
significantly influence catheter infection. The type of implanted CVC (159 port-a-cath in 153 patients and 71tunnelled
in 68) seems to affect the infection rate, this being lower in tunnelled (P=0.03). Infection ratewas lower in B vs A group
(Po0.001) with all types of catheters, suggesting the preventive role of very careful training. In particular, the incidence
of CVC-related sepsis was 6/1000 days of HPN (i.e. 6/1000 days of catheterization) in Group A and 3/1000 in Group B.
Systemic and antibiotic lock therapy was performedwith an 83% successful rate. Gram-positive bacteriawere themost
frequent CVC infection agents, which are usually eradicated by antibiotic therapy lasting 7 days. r 2002 Elsevier
Science Ltd. All rights reserved.Key words: venous catheter; infections; prevention;
treatment; HPN
Introduction
Home parenteral nutrition (HPN) is widely used to
prevent or correct malnutrition both in oncologic and
non-oncologic patients (1, 2). Despite its proved eﬃcacy,
HPN is burdened with some complications: the most
serious and frequent being catheter-related sepsis (3–5).
Recent studies reveal that common skin commensals,
such as Staphylococci, are frequently responsible for
central venous catheter (CVC)-related infections; fungi
and Gram-negative organisms are other, less frequent,
possible pathogens (6, 7). Nowadays, after short-term
systemic, antibiotic and catheter-lock therapy, most
infections are completely resolved and use of implanted
CVC restored (8).
The purpose of this retrospective study was to
examine in a sample of cancer- and non-cancer-bearing
patients on HPN in Naples district (South Italy): (1) the
prevalence of CVC infections, (2) infection rate accord-
ing to the type of implanted CVC, (3) the eﬀect of strict
preventive measures on CVC infections, (4) eﬀectiveness20of antibiotic therapeutic protocols on the occurred
infections.
Patients and methods
Two-hundred-twenty-one consecutive patients (96 M,
125 F; 72% oncologic, 28% non-oncologic) were
followed for 11,192 days of treatment between January
1995 and December 2000 at the outpatient clinic of the
Clinical Nutrition Unit of the University Hospital
Federico II in Naples. Patient age averaged 58718
years (min 27, max 78) and BMI 20.173.8 kg/m2 (min
15.2, max 22.8).
Patients have been divided into two groups:
1. Group A=110: 39 M, 71 F; aged 58716 years (min
29, max 74); BMI 20.673.2 kg/m2 (min 16.2, max
21.8); 81 oncologic, 29 not, followed from January
1995 to December 1998 (6573 days of HPN).
2. Group B=111: 57 M, 54 F; aged 57719 years
(min 27, max 78); BMI 19.472.8 kg/m2 (min 15.0,
max 21.7); 78 oncologic, 33 not, followed from
January 1999 to December 2000 (4619 days of
HPN).7
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(PN), with daily infusions, was started few days after
CVC implant, days of HPN approximately correspond-
ing to days of catheterization.
Before starting HPN, Group A patients, and/or their
care givers, were given an information sheet and
received oral instructions from the nutritional team,
attending two training sessions on the use of CVC when
HPN started; Group B patients, and/or their care givers,
instead, were given more detailed written instructions on
the aseptic management of CVC and how to avoid and
recognize complications, attended regularly at least six
both theoretical and practical training sessions carried
out by the nutritional team, and, when possible, were
monthly followed up in the clinic in order to examine
CVC conditions, to inspect the area of insertion and to
check their compliance to the given instructions.
In detail, instructions for Group B patients focused
on six main points:
1. Personal and environmental hygiene: Modalities and
duration of washing hands, using a nail brush and an
aseptic soap; using a sterile bearing surface; using
sterile gloves, disposable coats and cups during the
management of HPN.
2. More accurate procedure to prepare, under sterility,
the solution and eventual additions to the nutritional
solution (i.e. vitamins, trace elements, insulin, etc.)
3. Instructions about procedures to maintain sterility at
the beginning and at the end of infusions.
4. Use of special silicone perforable caps, to be applied
at the end of catheter, instead of rigid unscrewable
caps.
5. More care of CVC while not in use (skin cleansing,
sterile bandage).
6. How to recognize signs and symptoms of potential
septic complications and how to receive ﬁrst care.
The use of a mask, sterile gloves and a cap during the
management of HPN was mandatory for both groups,
but periodically recommended to patients in Group B.
Finally, Group B patients were carefully advised that
CVCs for HPN were to be used for PN only.
Rare exceptions were allowed on the occasion of
other i.v. treatments for selected patients with limited
peripheral venous access.
The diagnosis of systemic infection was made
according to the following traditional criteria (9, 10):
K increased body temperature and shivering during the
infusion of parenteral nutrition,
K identiﬁcation of the same pathogen in peripheral
blood and catheter cultures,
K elevated white blood cell count,
K exclusion of other possible sources of infection.
When CVC infection was suspected, parenteral
nutrition was given by peripheral route and CVC used
only for lock therapy, until central access was restored.
All septic episodes were separate infections because theidentiﬁed pathogens were always diﬀerent from the
previous ones; only in few cases, the same organism was
cultured from the same catheter but later than 2 months
after discontinuation of the antibiotic therapy.
Type of implanted CVC was in
1. Group A: 91 port-a-cath in 86 patients, 26 tunnelled
in 24.
2. Group B: 68 port-a-cath in 67 patients and 45
tunnelled in 44.
Patients were hospitalized on 10 occasions, when
catheter removal was necessary, i.e. culture results
yielded fungi or multiple infections or home antibiotic
therapy failed to eradicate the organism.
Systemic i.v. antibiotic and lock therapy was per-
formed for 7 consecutive days, according to the results
of blood cultures, and use of CVC restored after
negative results of blood cultures were obtained; details
are shown in Table 3.
Lock therapy consisted in intra-catheter injection of
the antibiotic diluted with 1–2ml of heparinized saline
solution in the ports and 2–3ml in the tunnelled
catheters. Total amounts were 3ml of diluted antibiotic
solution in the port-a-caths and 5ml in the tunnelled in
order to completely ﬁll the subcutaneous reservoir in the
ports and both the catheter lumen and the subcutaneous
tunnelled tract in tunnelled catheters. Lock therapy was
administered in bolus, once or twice a day, according to
the drug used (Table 3).
Statistical analysis
Data are expressed as mean 7 S.D. Age and BMI
diﬀerences between groups A and B were tested using
unpaired t-test. Diﬀerences in the rate of infections
between groups were tested using w2 analysis and
considered signiﬁcant when Po0.05.
A multivariate analysis has been performed with
logistic regression, using number of infections as
dependent variable; sex, type of catheter, type of disease
and group (A or B) as categorial covariates; duration of
HPN and age as non-categorical ones. Forward stepwise
analysis has also been performed.
Results
Sixty CVC-related infections occurred in 32 patients. In
Group A, 45 cases of CVC infection were recorded in 23
patients (six oncologic) corresponding to 21% of the
whole group. In Group B, only 15 CVC infections were
recorded in nine patients (one oncologic), i.e. 8% of the
whole group (P o0.001 Group A vs Group B).
The type of infected implant was 27 port-a-cath and
six tunnelled in Group A and 10 port-a-cath and one
tunnelled in Group B. One-hundred-eighty-nine patients
Table 1 Characteristics of HPN patients, number of infections and
their incidence in the two groups of patients, A and B, diﬀerently
trained
Group A B P
Total patients 110 111 N.S
Age 58716 57719 N.S
Sex (M/F) 39/71 57/54 N.S
BMI 20.673.2 19.472.8 N.S
Patients never infected 87 (79%) 102 (92%) 0.011
Infected patients 23 (21%) 9 (8%) 0.011
With one infection 13 4 N.S
With two infections 5 4 N.S
With three infections 3 1 N.S
With ﬁve infections 1 0 N.S
With eight infections 1 0 N.S
Total infections (n) 45 15 0.000
Incidence (n/HPN days) 6.8/1000 3.2/1000 0.000
Table 2a Type of catheters used for Groups A and Bw
Port-a-cath Tunnelled P
Group A 91 (78%) 26 (22%) 0.000
Group B 68 (60%) 45 (40%) 0.004
Total 159 (69%) 71 (31%) 0.000
Infected 37 (23%) 7 (10%) 0.032
wAbsolute number (relative percentage); P expresses the diﬀerence
between groups.
Table 2b Number and type of catheters, total infections and their
incidence, according to the type of catheter: port-a-cath and tunnelled
in Groups A and B, respectively
Port-a cath Tunnelled Infection rate
Total
(n)
Infected
(n)
% Total
(n)
Infected
(n)
% P (port
vs tunn)
Group A 91 27 30* 26 6 23** NS
Group B 68 10 15* 45 1 2** 0.051
Total 159 37 23 71 7 10 0.032
*A vs B P= 0.044. **A vs B P=0.014.
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(79%) in Group A and 102 patients (92%) in Group B
(A vs B: P=0.01). General data on infections and
incidences are summarized in Table 1.
According to the type of implanted CVC, 37
infections were observed in those patients with 159
implanted port-a-cath and seven in patients with 71
tunnelled catheters, corresponding, respectively, to an
infection rate of 23% of implanted ports and 10% of
tunnelled catheters, the diﬀerence being signiﬁcant
(P=0.03) in the whole population and in particular, in
Group B (P=0.05).
In particular, in Group A, 27 port-a-cath and six
tunnelled catheter infections were recorded, correspond-
ing to 30% and 23% infection rates, respectively; in
Group B, the incidence was 15% (10/68) and 2% (1/45)
for port-a-cath and tunnelled, respectively (Tables 2a
and 2b).
While comparing Groups A and B, there was a
signiﬁcant decrease in infection rate either with port-a-
cath (P=0.04) and tunnelled implanted (P=0.01)
catheters.
The overall annual incidence of CVC infections
(number of infections/1000 days of HPN) signiﬁcantly
decreased from more than 6/1000 in Group A to less
than 3/1000 in Group B, the diﬀerence being signiﬁcant
(Po0.001).
Furthermore, in Group A, two major septic compli-
cations, i.e. septic shock during manoeuvres for blood
sampling from CVC were also recorded and accordingly
treated.
As far as pathogens were concerned Staphylococcus
epidermidis was responsible for 33/60 infections (55%);
other Gram-positive occurred in 11/60 (18%); Gram-
negative accounted for 15% (9/60), whereas fungi only
2% (1/60). Finally, six cases (10%) were polymicrobial.
In conclusion, Gram-positive bacteria represented
73% of the isolated pathogens. Systemic and antibiotic
lock treatment was performed according to the results of
blood cultures as summarized in Table 3. Bacteria
involved in Group B infections (14 S. epidermidis and 1
Escherichia coli) were all eradicated, while in Group A,seven infections (6 polymicrobial and 1 Candida
albicans) were a priori considered not treatable with
antibiotics. After antibiotic therapy, infections were
completely resolved in 50 cases (83%) and use of CVC
restored after a negative control blood culture from
CVC.
CVC was immediately removed in one case due to
mycotic infection (C. albicans), in six patients because of
multiple infections and in other three (two Serratia
marcescens and one Xanthomonas spp.) due to antibiotic
resistance; as previously mentioned all patients were in
Group A. Removed catheters were port in seven cases
and tunnelled in three. The average duration of the
replaced catheter before the occurrence of a new
infection with a diﬀerent organism was 1927120 days
(min 63, max 365) and several pathogens were involved
(S. epidermidis in most of the cases). When CVC
removal was necessary, catheter tip was cultured to
conﬁrm the cause of infection and the same pathogen
present in the blood was always observed.
A multivariate analysis with logistic regression,
carried out using number of infections as dependent
variable, showed that the duration of HPN (Po 0.001;
OR=0.9), type of catheter (P=0.009; OR=0.012), and
type of disease (P=0.033; OR=4.92) signiﬁcantly
inﬂuence catheter infection (Table 4). Using a forward
stepwise analysis, days of HPN turned out to be the
major determinant of CVC infection, followed by group
(A or B) (P=0.013).
Discussion
Catheter-related bloodstream infection is a severe and
the most frequent complication of HPN, being a
common cause of hospitalization (11, 12). In the past,
the general approach to catheter-related infections in
Table 3 Antibiotic treatment in the 50 successfully treated infections
Pathogens
Antibiotic therapy
Infections
Groups
Antibiotics
Daily dose
Days of
treatment(n) A (n) B (n) Lock Systemic (i.v.)
33 19 14 S. epidermidis Clindamicine 300mg 2 600mg 2 7
10 10 0 S. aureus, S. auricolaris, S. werneri, S. sanguis,
S. sciuri, S. hominis
Teicoplanine 100mg 1 200mg 1 7
5 5 0 S. liquefaciens, E. cloacae, B. diastasonis Netilmicine 150mg 1 150mg 2 7
2 1 1 E. coli, S. haemoliticus Piperacilline 500mg 2 2 g 2 7
Table 4 Results of multivariate analysis performed with logistic
regression using number of infection as dependent variablew
Tested variables P OR Conﬁdence interval
Age 0.20 0.97 0.93–1.01
Sex 0.20 1.90 0.70–5.15
Disease 0.033 4.92 1.13–21.3
Days of HPN 0.000 0.97 0.95–0.98
Group 0.46 0.70 0.27–1.82
Type of catheter 0.0092 0.12 0.02–0.59
wUsing a forward stepwise analysis, the variable group signiﬁcantly
inﬂuences CVC infection rate (P=0.01).
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Fig. 1 Annual incidence of CVC infections in Group A (1995–1998;
white bars) and in Group B (1999–2000; black bars). Group A vs
Group B average incidence: Po 0.05.
210 PREVENTION AND TREATMENT OF CVC–RELATED INFECTIONS IN HPNpatients receiving HPN was CVC removal and its
replacement after systemic antibiotic treatment (13, 14).
In the last few decades, new available antibiotics as
well as lock therapy, because of high drug concentra-
tions in the catheter’s lumen (8), have shortened the
duration and increased the success rate of treatment of
infected CVC (4, 15). Therefore, nowadays most of the
infected catheters can be sterilized by antibiotic and
local care (16); hence a treatment attempt is worthwhile
with some well-known contraindications, i.e. polymi-
crobial or fungal infections where prompt CVC removal
is advisable (17).
Prevention plays a fundamental role in the manage-
ment of CVC infections in patients on HPN and the
nutritional team, including nursing and local care, can
eﬀectively reduce infection rates and severity thus
increasing catheter longevity (16, 18, 19).
Also in our experience, it appears that strict adherence
to protocols and close monitoring lead to a decreased
sepsis rate with increased catheter longevity (Fig. 1).
The careful information given to the patients leads to
a signiﬁcant decrease of CVC-related sepsis both in
oncologic and in non-oncologic patients and with both
types of implanted catheters.
Furthermore, the experience gained by the team plays
a central role conﬁrming that HPN is not a common
treatment and must be performed by well-trained,
experienced teams, in particular, to prevent and treat
major complications such as sepsis (5, 19).
The nutritional team has, therefore, a central role in
the training of patients and/or their care givers (both
nurses or relatives), in particular, emphasizing thorough
attention to the aseptic management of implanted
catheters (19).
The majority of these infections in our outpatient’s
population was due to Gram-positive organisms suscep-tible to either Clindamicine or Netilmicine according to
microbiological reports; Teicoplanine was a reasonable
alternative to this combination in case of bacterial
resistance.
Following multivariate analysis, also the use of port-
a-cath appeared as a determinant of catheter infection,
its role being important.
Therefore, implanted port-a-cath seems to be asso-
ciated with a higher risk than tunnelled catheters, the
diﬀerence being statistically signiﬁcant (P=0.03). On
the other hand, this result does not mean that use of
port-a-cath catheters is not advisable.
In some cases and, above all in oncologic patients,
port-a-cath had been previously implanted and also
used for chemotherapy, and only subsequently for HPN.
Tunnelled catheters had usually been implanted
speciﬁcally for HPN, therefore a more limited manip-
ulation was guaranteed under these circumstances.
Furthermore, tunnelled catheters have a subcutaneous
tunnelled tract (about 5–10 cm) that lengthens the
distance between external skin and bloodstream, thus
reducing the likelihood of germ entry; moreover, they
have a dacron cuﬀ that inhibits migration of micro-
organisms by stimulating growth of surrounding tissue,
providing a natural anchor for the catheter (1). Never-
theless, careful instructions were able to improve
infection rate in patients on HPN either with tunnelled
or port-a-cath implanted catheters. On the other hand, a
longer proportion of patients in Group B used a
tunnelled catheter, suggesting that the choice of
implantable catheter was perhaps more appropriate in
the consideration of long-term HPN.
CLINICAL NUTRITION 211Few data are available about host factors that
contribute to HPN infections (20, 21). In our study,
age, sex, clinical condition, cultural level did not appear
to have a role as predictive factors for CVC infection
(data not shown). On the other hand, type of disease
signiﬁcantly inﬂuences CVC infection rate. Duration of
HPN is the main predictor of infection, followed by type
of catheter and type of disease; besides, the improved
training of patients and care givers and the experience
gained over time by the nutritional team are able to
inﬂuence the infection rate of implanted CVC.
The choice of catheters to be implanted also seems to
play a role giving priority to the use of tunnelled more
than port-a-cath catheters (22). Furthermore, in our
population, Gram-positive bacteria are frequently respon-
sible for CVC infections; these infections can be treated,
particularly when due to a single pathogen, and in these
cases, short-term antibiotic lock therapy, associated with
systemic treatment, allows complete recovery of the
central catheter after only 7 days of treatment. The
concomitant presence of Gram-negative bacteria as well
as fungi required catheter removal (15, 23).
Unfortunately, several factors limited our study: (1) the
small number of antibiotics tested by the microbiological
service; (2) consequently, few antibiotics turned out to be
active against isolated germs; (3) few tested antibiotics
were available in injectable formulations.
However, this retrospective study increased our
experience on the treatment of CVC infections also as
far as the selection of antibiotics to be used is concerned.
In fact, by early 2001, no more than a single antibiotic
for lock and systemic treatment is used, but a combina-
tion of two or plus antibiotics with diﬀerent mechan-
isms, site and spectrum of action, in order to avoid
bacterial resistance. In particular, drugs with more
speciﬁc spectrum and lower MIC are currently used
for antibiotic lock therapy and those with wider
spectrum for systemic therapy.
In conclusion, HPN patients need clear information
about what are infectious complications as well as clear
and continuous instructions on the use of implanted
catheter by a well-trained team. Tunnelled catheters also
in our experience show a lower risk of infection.
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